{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:54:40Z","timestamp":1789048480396,"version":"build-2803163510"},"reference-count":74,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018896","name":"Sylvester Comprehensive Cancer Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018896","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/0552r4b12","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"United States NIH\/NCI","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Overexpression of transferrin receptor (TFR1) is common in cancer and may be associated with inferior treatment outcomes. Due to these patterns and TFR1\u2019s essential role in iron metabolism, the protein has been targeted for cytotoxic drug delivery. More recently, increased TFR1 expression has been linked to tumor microenvironment (TME) infiltration by immune effectors in selected tumors, but a comprehensive assessment of the genomic landscape associated TFRC (the gene encoding TFR1) expression has not been conducted. Methods: By utilizing a pan-cancer database of 93,248 patients with whole-exome and whole-transcriptome sequencing, we assessed TFRC-associated multiomic patterns. Results: We found that high TFRC expression correlates with significantly worse overall survival in multiple common solid tumor types, a higher tumor mutational burden (TMB), an increase in infiltrating effector cells with upregulated immune checkpoint markers within the TME, and increased frequency of specific high-risk genomic alterations. Further assessment in cell line models revealed increased susceptibility to cytotoxic T cells when iron metabolism is elevated, despite upregulation of the checkpoint ligand PD-L1. Conclusions: High TFRC expression, therefore, indicates worse clinical risk across multiple common tumor types but potentially increased susceptibility to cytotoxic immune effectors, informing the development of TFR1 biomarker-driven therapeutic strategies.<\/jats:p>","DOI":"10.3390\/cancers18091402","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:26:41Z","timestamp":1777382801000},"page":"1402","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transferrin Receptor Overexpression in Solid Tumors Is Associated with Inflamed Microenvironments and Upregulated Immune Checkpoints, with Implications for Immunotherapy Sensitivity"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-1797","authenticated-orcid":false,"given":"Asaad","family":"Trabolsi","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Lekakis","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Commisso","sequence":"additional","affiliation":[{"name":"University of Miami, Coral Gables, FL 33124, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, AZ 85040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8031","authenticated-orcid":false,"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, AZ 85040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Liu","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Ma","sequence":"additional","affiliation":[{"name":"LSU-LCMC Health Cancer Center, Louisiana State University Health Science Center, New Orlans, LA 70112, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave S. B.","family":"Hoon","sequence":"additional","affiliation":[{"name":"St. John\u2019s Cancer Institute, Providence Healthcare Services, Santa Monica, CA 90404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanzeng","family":"Wei","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA 19111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-9655","authenticated-orcid":false,"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Masonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-2777","authenticated-orcid":false,"given":"Artavazd","family":"Arumov","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1842-228X","authenticated-orcid":false,"given":"Jonathan H.","family":"Schatz","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The Cancer-Immunity Cycle: Indication, Genotype, and Immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Vaddepally, R.K., Kharel, P., Pandey, R., Garje, R., and Chandra, A.B. (2020). Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers, 12.","DOI":"10.3390\/cancers12030738"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-Term Outcomes Following CAR T Cell Therapy: What We Know so Far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New Immune Cell Engagers for Cancer Immunotherapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_8","unstructured":"(2024). FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma. FDA, Available online: https:\/\/www.asco.org\/news-initiatives\/policy-news-analysis\/fda-grants-accelerated-approval-lifileucel-unresectable-or."},{"key":"ref_9","unstructured":"(2024). FDA Approves Tebentafusp-Tebn for Unresectable or Metastatic Uveal Melanoma. FDA, Available online: https:\/\/www.asco.org\/news-initiatives\/policy-news-analysis\/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal."},{"key":"ref_10","unstructured":"(2024). FDA Grants Accelerated Approval to Tarlatamab-Dlle for Extensive Stage Small Cell Lung Cancer. FDA, Available online: https:\/\/www.asco.org\/news-initiatives\/policy-news-analysis\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune Checkpoint Therapy for Solid Tumours: Clinical Dilemmas and Future Trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T Cell Therapy and the Tumor Microenvironment: Current Challenges and Opportunities","volume":"25","author":"Fonkoua","year":"2022","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth","volume":"41","author":"Joyce","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"(2024, August 28). Therapeutic Targeting of the Tumor Microenvironment|Cancer Discovery|American Association for Cancer Research. Available online: https:\/\/aacrjournals-org.access.library.miami.edu\/cancerdiscovery\/article\/11\/4\/933\/665833\/Therapeutic-Targeting-of-the-Tumor.","DOI":"10.1158\/2159-8290.CD-20-1808"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eabo3605","DOI":"10.1126\/scitranslmed.abo3605","article-title":"Combination Cancer Immunotherapies: Emerging Treatment Strategies Adapted to the Tumor Microenvironment","volume":"14","author":"Kirchhammer","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clim.2006.06.006","article-title":"The Transferrin Receptor Part II: Targeted Delivery of Therapeutic Agents into Cancer Cells","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clim.2006.06.010","article-title":"The Transferrin Receptor Part I: Biology and Targeting with Cytotoxic Antibodies for the Treatment of Cancer","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3495","article-title":"Iron and Cancer: More Ore to Be Mined","volume":"13","author":"Torti","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1038\/onc.2017.11","article-title":"Iron Addiction: A Novel Therapeutic Target in Ovarian Cancer","volume":"36","author":"Basuli","year":"2017","journal-title":"Oncogene"},{"key":"ref_20","first-page":"916","article-title":"Transferrin Receptor 1 in Cancer: A New Sight for Cancer Therapy","volume":"8","author":"Shen","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s13402-023-00828-3","article-title":"Iron Metabolism in Colorectal Cancer: A Balancing Act","volume":"46","author":"Cardoso","year":"2023","journal-title":"Cell. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wang, Y., Ohara, T., Chen, Y., Hamada, Y., Li, C., Fujisawa, M., Yoshimura, T., and Matsukawa, A. (2023). Highly Metastatic Subpopulation of TNBC Cells Has Limited Iron Metabolism and Is a Target of Iron Chelators. Cancers, 15.","DOI":"10.3390\/cancers15020468"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.2147\/CMAR.S198911","article-title":"Downregulation of TfR1 Promotes Progression of Colorectal Cancer via the JAK\/STAT Pathway","volume":"11","author":"Cui","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/0008-5472.CAN-20-2674","article-title":"Optimized Doxorubicin Chemotherapy for Diffuse Large B-Cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors","volume":"81","author":"Arumov","year":"2021","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2022.40.16_suppl.3120","article-title":"Pan-Cancer Association between Increased Iron Utilization and Poor Prognosis Highlights Potential of Transferrin Receptor-Targeting Therapies in Multiple Tumor Types","volume":"40","author":"Trabolsi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-009-0345-x","article-title":"Transferrin Receptor (CD71) Is a Marker of Poor Prognosis in Breast Cancer and Can Predict Response to Tamoxifen","volume":"119","author":"Habashy","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41417-019-0078-x","article-title":"Transferrin Receptor-Involved HIF-1 Signaling Pathway in Cervical Cancer","volume":"26","author":"Xu","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"ref_28","first-page":"1259","article-title":"Phase Ia Trial of Murine Immunoglobulin A Antitransferrin Receptor Antibody 42\/6","volume":"1","author":"Brooks","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1158\/0008-5472.CAN-10-0938","article-title":"Development of Human Single-Chain Antibodies to the Transferrin Receptor That Effectively Antagonize the Growth of Leukemias and Lymphomas","volume":"70","author":"Goenaga","year":"2010","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2023.41.16_suppl.2613","article-title":"High Transferrin Receptor Expression Marks Tumors with Increased Immune-Effector Infiltration and Expression of Targetable Checkpoint Molecules: Results of a Multi-Cancer Analysis in Solid Tumors","volume":"41","author":"Trabolsi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.celrep.2020.02.049","article-title":"Transferrin Receptor Is a Specific Ferroptosis Marker","volume":"30","author":"Feng","year":"2020","journal-title":"Cell Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis Turns 10: Emerging Mechanisms, Physiological Functions, and Therapeutic Applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.molmed.2021.06.014","article-title":"Ferroptosis in the Tumor Microenvironment: Perspectives for Immunotherapy","volume":"27","author":"Xu","year":"2021","journal-title":"Trends Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8+ T Cells Regulate Tumour Ferroptosis during Cancer Immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_36","unstructured":"(2024, September 20). The Genome Aggregation Database (gnomAD)|gnomAD Browser. Available online: https:\/\/gnomad.broadinstitute.org\/news\/2017-02-the-genome-aggregation-database\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e000147","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing Guidelines to Harmonize Tumor Mutational Burden (TMB): In Silico Assessment of Variation in TMB Quantification across Diagnostic Platforms: Phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of Tumour Mutational Burden with Outcomes in Patients with Advanced Solid Tumours Treated with Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s43018-024-00752-x","article-title":"Tissue-Specific Thresholds of Mutation Burden Associated with Anti-PD-1\/L1 Therapy Benefit and Prognosis in Microsatellite-Stable Cancers","volume":"5","author":"Muquith","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon Provides Fast and Bias-Aware Quantification of Transcript Expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat. Methods"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and Pharmacological Modulators of the Tumor Immune Contexture Revealed by Deconvolution of RNA-Seq Data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1535-7163.MCT-21-0193","article-title":"Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody\u2013Drug Conjugate","volume":"21","author":"Singh","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.medj.2022.11.006","article-title":"A Novel Bispecific Antibody Able to Pass the Blood-Brain Barrier and Therapeutically Engage within the Brain","volume":"3","author":"Thomsen","year":"2022","journal-title":"Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1158\/0008-5472.CAN-23-1796","article-title":"Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy","volume":"84","author":"Mu","year":"2024","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/JEnvironPatholToxicolOncol.2023049084","article-title":"TFR1-Mediated Iron Metabolism Orchestrates Tumor Ferroptosis and Immunity in Non-Small Cell Lung Cancer","volume":"43","author":"Wang","year":"2024","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s10637-021-01070-0","article-title":"System Xc\u2212: A Key Regulatory Target of Ferroptosis in Cancer","volume":"39","author":"Liu","year":"2021","journal-title":"Invest. New Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1091\/mbc.E20-02-0129","article-title":"Unconventional Endocytosis and Trafficking of Transferrin Receptor Induced by Iron","volume":"32","author":"Gammella","year":"2021","journal-title":"Mol. Biol. Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.2452485","article-title":"Iron-Responsive Elements: Regulatory RNA Sequences That Control mRNA Levels and Translation","volume":"240","author":"Casey","year":"1988","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8872","DOI":"10.1038\/s41598-023-35978-9","article-title":"GPX4 Overexpressed Non-Small Cell Lung Cancer Cells Are Sensitive to RSL3-Induced Ferroptosis","volume":"13","author":"Kim","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/1535-7163.MCT-23-0548","article-title":"INA03: A Potent Transferrin-Competitive Antibody\u2013Drug Conjugate against CD71 for Safer Acute Leukemia Treatment","volume":"23","author":"Bratti","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1182\/blood-2023-185717","article-title":"Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R\/R) Acute Leukemias","volume":"142","author":"Garciaz","year":"2023","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-21-0194","article-title":"Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies","volume":"27","author":"Johnson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/his.13847","article-title":"Transferrin Receptor 1 Overexpression Is Associated with Tumour De-Differentiation and Acts as a Potential Prognostic Indicator of Hepatocellular Carcinoma","volume":"75","author":"Adachi","year":"2019","journal-title":"Histopathology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107052","DOI":"10.18632\/oncotarget.22323","article-title":"Transferrin Receptor 1 Upregulation in Primary Tumor and Downregulation in Benign Kidney Is Associated with Progression and Mortality in Renal Cell Carcinoma Patients","volume":"8","author":"Greene","year":"2017","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3892\/or.2014.2981","article-title":"Overexpression of Transferrin Receptor CD71 and Its Tumorigenic Properties in Esophageal Squamous Cell Carcinoma","volume":"31","author":"Chan","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ahmadi, N., Vidanapathirana, G., and Gopalan, V. (2025). Crossroads of Iron Metabolism and Inflammation in Colorectal Carcinogenesis: Molecular Mechanisms and Therapeutic Perspectives. Genes, 16.","DOI":"10.3390\/genes16101166"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Huang, L., Li, W., Lu, Y., Ju, Q., and Ouyang, M. (2023). Iron Metabolism in Colorectal Cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1098501"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"EMBR202051162","DOI":"10.15252\/embr.202051162","article-title":"The Deubiquitinase OTUD1 Enhances Iron Transport and Potentiates Host Antitumor Immunity","volume":"22","author":"Song","year":"2021","journal-title":"EMBO Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2207693","DOI":"10.1002\/advs.202207693","article-title":"Transferrin Receptor-Mediated Iron Uptake Promotes Colon Tumorigenesis","volume":"10","author":"Kim","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/CMAR.S503932","article-title":"Iron-Dependent Cell Death: Exploring Ferroptosis as a Unique Target in Triple-Negative Breast Cancer Management","volume":"17","author":"Tan","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"115866","DOI":"10.1016\/j.biopha.2023.115866","article-title":"Ferroptosis Induction via Targeting Metabolic Alterations in Triple-Negative Breast Cancer","volume":"169","author":"Wang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ma, S., Dielschneider, R.F., Henson, E.S., Xiao, W., Choquette, T.R., Blankstein, A.R., Chen, Y., and Gibson, S.B. (2017). Ferroptosis and Autophagy Induced Cell Death Occur Independently after Siramesine and Lapatinib Treatment in Breast Cancer Cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182921"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40001-024-01688-9","article-title":"TFRC, Associated with Hypoxia and Immune, Is a Prognostic Factor and Potential Therapeutic Target for Bladder Cancer","volume":"29","author":"Tang","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wu, H., He, H., Huang, J., Wang, C., Dong, Y., Lin, R., Cheng, Z., Qiu, Q., and Hong, L. (2022). Identification and Validation of Transferrin Receptor Protein 1 for Predicting Prognosis and Immune Infiltration in Lower Grade Glioma. Front. Mol. Neurosci., 15.","DOI":"10.3389\/fnmol.2022.972308"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Yang, C., Li, J., Guo, Y., Gan, D., Zhang, C., Wang, R., Hua, L., Zhu, L., Ma, P., and Shi, J. (2022). Role of TFRC as a Novel Prognostic Biomarker and in Immunotherapy for Pancreatic Carcinoma. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.756895"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.omto.2020.01.003","article-title":"Gene Silencing of Transferrin-1 Receptor as a Potential Therapeutic Target for Human Follicular and Anaplastic Thyroid Cancer","volume":"16","author":"Campisi","year":"2020","journal-title":"Mol. Ther. -Oncolytics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1007\/s12035-024-03990-3","article-title":"Increased Expression of Transferrin Receptor 1 in the Brain Cortex of 5xFAD Mouse Model of Alzheimer\u2019s Disease Is Associated with Activation of HIF-1 Signaling Pathway","volume":"61","author":"Petralla","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2204514","DOI":"10.1002\/advs.202204514","article-title":"Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer","volume":"10","author":"Chung","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wang, S., Chen, S., Ying, Y., Ma, X., Shen, H., Li, J., Wang, X., Lin, Y., Liu, B., and Zheng, X. (2021). Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.676142"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"18302","DOI":"10.1038\/s41598-023-45284-z","article-title":"SLC7A11, a Potential Immunotherapeutic Target in Lung Adenocarcinoma","volume":"13","author":"Shan","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1111\/cas.15760","article-title":"SLC3A2 Promotes Tumor-associated Macrophage Polarization through Metabolic Reprogramming in Lung Cancer","volume":"114","author":"Li","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"17917","DOI":"10.1038\/s41598-024-68779-9","article-title":"CD98 Heavy Chain Protein Is Overexpressed in Non-Small Cell Lung Cancer and Is a Potential Target for CAR T-Cell Therapy","volume":"14","author":"Yaga","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific Antibodies: Advancing Precision Oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1402\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:18:26Z","timestamp":1777522706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":74,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18091402"],"URL":"https:\/\/doi.org\/10.3390\/cancers18091402","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}